EFM
KRYS icon

E Fund Management’s Krystal Biotech KRYS Stock Holding History

E Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Sell
1,323
-958
-42% -$286K 0.01% 271
2026
Q1 		$589K Buy
+2,281
New +$607K 0.02% 253
2025
Q2 		$532K Buy
3,870
+1,612
+71% +$237K 0.03% 221
2025
Q1 		$407K Buy
2,258
+324
+17% +$54.5K 0.02% 247
2024
Q4 		$303K Sell
1,934
-1,007
-34% -$179K 0.02% 312
2024
Q3 		$535K Buy
2,941
+402
+16% +$77.5K 0.03% 187
2024
Q2 		$466K Buy
2,539
+17
+0.7% +$2.85K 0.03% 182
2024
Q1 		$449K Sell
2,522
-1,973
-44% -$274K 0.03% 174
2023
Q4 		$558K Buy
4,495
+808
+22% +$89.6K 0.04% 138
2023
Q3 		$428K Buy
3,687
+830
+29% +$101K 0.03% 153
2023
Q2 		$335K Sell
2,857
-631
-18% -$64.4K 0.03% 203
2023
Q1 		$279K Buy
3,488
+260
+8% +$20.4K 0.02% 238
2022
Q4 		$256K Sell
3,228
-363
-10% -$26.9K 0.02% 256
2022
Q3 		$250K Sell
3,591
-217
-6% -$15.7K 0.02% 264
2022
Q2 		$250K Buy
3,808
+797
+26% +$49.6K 0.02% 263
2022
Q1 		$200K Buy
+3,011
New +$188K 0.01% 298

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management's KRYS Position: Q2 2026 in Review

E Fund Management reduced its Krystal Biotech (KRYS) stake by 42% in Q2 2026, selling an estimated $286K and leaving 1,323 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #271.

E Fund Management first reported a position in KRYS in Q1 2022 and has held it in 16 quarters since. The position peaked at $589K in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • E Fund Management held 1,323 shares of Krystal Biotech worth $492K as of Q2 2026.
  • E Fund Management sold 958 Krystal Biotech shares in Q2 2026, an estimated $286K.
  • Krystal Biotech made up 0.01% of E Fund Management's portfolio in Q2 2026, its #271 holding.
  • E Fund Management first reported a position in Krystal Biotech in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Krystal Biotech position peaked at $589K in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.